about
Oncogenic ERBB3 mutations in human cancersSuppressor of fused regulates Gli activity through a dual binding mechanismDiscovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactionsMonovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agentMechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancersA novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivoMetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survivalWW- and SH3-domain interactions with Epstein-Barr virus LMP2A.Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration-effect data to support clinical development.The LMP2A ITAM is essential for providing B cells with development and survival signals in vivoWidespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.A transgene insertion creating a heritable chromosome deletion mouse model of Prader-Willi and angelman syndromesImmuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab.Pharmacokinetic drivers of toxicity for basic molecules: strategy to lower pKa results in decreased tissue exposure and toxicity for a small molecule Met inhibitor.FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth.Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic-pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihyLMP2A survival and developmental signals are transmitted through Btk-dependent and Btk-independent pathways.Structure of SAP18: a ubiquitin fold in histone deacetylase complex assembly.A comprehensive genetic map of the mouse genome.PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.Quantitative locus analysis of airway hyperresponsiveness in A/J and C57BL/6J mice
P50
Q24293022-9FED3E8F-D982-4241-9A97-4C0AE03BDC0EQ24561743-67A5DAC7-D697-44CC-BFEC-44E8575F7B57Q27678556-7761E219-388D-483C-9D10-096AA2D8C654Q27679191-34EF45ED-34DE-4705-96FB-14EB9AC4C534Q27685364-A49A8599-1FC1-4856-8CF7-A4FFE1EC2651Q27852131-D9361493-BC58-41B1-99D8-9FD642449127Q28270305-7CF57DFE-189F-4FCB-8CF9-8B3F6C5A2D0DQ28282398-EFB7B1B0-F253-41C9-A790-F66685DFD76BQ30168997-49B08EBE-BD2E-443E-BA85-394794B78A33Q30657838-376D892E-2DD5-4F02-9790-07835F4229D4Q33604616-85355373-F415-40C8-81AF-9E2E5E737BD3Q34032640-1D9C40FA-D291-4025-823F-718A4EA240B7Q35601037-1C586A0B-5FEE-40A7-A3A4-837A6693971AQ37696629-1C2283E2-EE88-4184-8F1D-537DE687F322Q39246801-6ACF66BA-FC7C-4B8F-ACE5-AA01E2DE2D10Q39270066-30B864C2-60CB-479C-8CF4-E580100DA89BQ39399836-C7C82670-31F3-4F65-A099-205B6104416BQ39442875-97185C8C-AA46-40EA-A50B-64A6EB26E753Q39443947-4915E1DF-6AB4-4362-9D05-280C51F5A378Q39616531-486AF7CF-DB8A-40A8-A7D5-F655CA7D782DQ43905603-88E39E7E-36C9-4AD4-819C-DCE5EB2797FCQ46770660-190B989A-6ABA-4246-9515-A424B0145F84Q54223711-4F02ADC9-1680-437F-971B-18199B2F4EB7Q54478528-458BFC83-A66D-4DC4-8009-CA3406D45D27Q71721174-C58305B3-BBC6-4C6E-BC26-B4AC99A56E67
P50
description
hulumtues
@sq
researcher
@en
հետազոտող
@hy
name
Mark Merchant
@ast
Mark Merchant
@en
Mark Merchant
@es
Mark Merchant
@nl
Mark Merchant
@sl
type
label
Mark Merchant
@ast
Mark Merchant
@en
Mark Merchant
@es
Mark Merchant
@nl
Mark Merchant
@sl
prefLabel
Mark Merchant
@ast
Mark Merchant
@en
Mark Merchant
@es
Mark Merchant
@nl
Mark Merchant
@sl
P106
P1153
21035204200
P21
P31
P496
0000-0003-0690-8581